**Supplemental Table 6** Mean Changes in Visual Acuity and Central Subfield Thickness Compared to Baseline for Eyes Treated with Intravitreal Bevacizumab Monotherapy Stratified by Presenting Visual Acuity Groups (Complete Case Analysis)

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Changes from Baseline** | **Overall** | | | **Moderate to Severe Visual Impairment** | | | **Mild Visual Impairment** | | |
| **Mean** | **95% CI** | **P Value** | **Mean** | **95% CI** | **P Value** | **Mean** | **95% CI** | **P Value** |
| **Month 12** |  |  |  |  |  |  |  |  |  |
| Number of eyes, n |  | 308 |  |  | 220 |  |  | 88 |  |
| VA, ETDRS letters | +7.1 | +4.7 to  +9.4 | <0.001 | +8.5 | +5.8 to +11.2 | <0.001 | +3.1 | -1.2 to +7.5 | 0.157 |
| CSFT, µm | -126.1 | -148.4 to -103.9 | <0.001 | -145.3 | -170.6 to -120.0 | <0.001 | -74.7 | -114.0 to -35.5 | <0.001 |
| **Month 24** |  |  |  |  |  |  |  |  |  |
| Number of eyes, n | 225 | | | 156 | | | 69 | | |
| VA, ETDRS letters | +4.9 | +2.2 to +7.6 | <0.001 | +8.3 | +5.1 to +11.4 | <0.001 | -3.1 | -7.9 to +1.7 | 0.211 |
| CSFT, µm | -172.8 | -199.2 to -146.4 | <0.001 | -214.9 | -246.0 to -183.8 | <0.001 | -78.6 | -123.2 to -33.9 | 0.001 |
| **Month36** |  |  |  |  |  |  |  |  |  |
| Number of eyes, n | 150 | | | 101 | | | 49 | | |
| VA, ETDRS letters | +2.5 | -0.9 to +5.9 | 0.144 | +3.9 | -0.2 to +8.0 | 0.060 | -1.7 | -7.5 to +4.0 | 0.553 |
| CSFT, µm | -156.5 | -187.3 to -125.7 | <0.001 | -180.2 | -217.4 to -142.9 | <0.001 | -96.5 | -147.0 to -46.0 | <0.001 |
| *VA = visual acuity, CI = confidence interval, ETDRS = Early Treatment Diabetic Retinopathy Study*  *CSFT = central subfield thickness* | | | | | | | | | |